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Introduction
For decades, cardiac surgeons have performed coronary 
surgery with cardiopulmonary bypass (CPB) and cardioplegia-
induced cardiac arrest, the on-pump technique (ONCAB), 
which provides a motionless and bloodless surgical 
field, this at the expense of potentially negative sequelae 
including blood trauma, activation of systemic inflammatory 
responses, non-pulsatile flow, aortic cannulation and 
clamping with possible embolization of air or atherosclerotic 
debris and systemic hemodilution (1).
Because of these detrimental aspects, ONCAB has been 
challenged in recent years by off-pump coronary artery 
bypass surgery (OPCAB), which avoids the use of CPB. 
This has triggered a large number of randomized clinical 
trials (RCTs) and retrospective analyses addressing the 
clinical outcomes of the two techniques. There seems to 
be convincing evidence that OPCAB reduces the risk of 
early postoperative morbidity such as myocardial infarction, 
pulmonary dysfunction, abnormal renal function, atrial 
fibrillation, blood product transfusion, intensive care unit 
and hospital stay (2-14). However, concerns persist with 
respect to the impact of OPCAB on long-term mortality 
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and freedom from re-intervention (15-18) with some studies 
reporting a higher risk of incomplete revascularization 
and graft failure (19,20). Despite the potential benefits of 
OPCAB, recent data shows that only a minority of CABG 
operations worldwide (about 15% to 20%) are carried out 
with this technique (21).
Surgeons might be reluctant to commit to OPCAB 
because of concerns that the technique requires distal 
anastomoses to be performed on the beating heart, 
potentially compromising long-term graft patency. These 
concerns seem not to apply in large-volume centers and for 
surgeons who have crossed their learning curve (22,23). 
Methods
We conducted a literature search through PubMed, 
EMBASE, the Web of Science, the Cochrane Library 
and Google Scholar. No language, publication date or 
publication status was imposed. Suitable papers were 
individually analyzed and results were tabulated in a 
spreadsheet to categorize and organize the information. 
The main articles were presented as well in a table (Table 1).
Results
A general view of recent randomized controlled trials
The largest trials until now are the Randomized On/Off 
Bypass (ROOBY) trial (28) and the CABG Off or On Pump 
Revascularization Study (CORONARY) (29). 
The ROOBY trial enrolled 2,203 patients from the 
Veterans Affairs (VA) system scheduled for urgent or 
elective CABG to either OPCAB or ONCAB. The primary 
long-term end point was a composite of death from any 
cause, a repeat revascularization procedure, or a nonfatal 
myocardial infarction within 1 year after surgery. The 
results showed a significantly higher rate of the composite 
long-term outcome with OPCAB when compared with 
ONCAB (9.9% vs. 7.4%; RR =1.33; 95% CI, 1.01–1.76; 
P=0.04). The 1-year patency rate of arterial grafts was lower 
in OPCAB (92.9%) than ONCAB (94.8%) although this 
difference was not statistically significant (P=0.13).
Recently, the results of the CORONARY trial at 
1 year have been published (29): authors compared OPCAB 
with ONCAB in 4,752 patients from 19 countries on 
5 continents. They found no significant differences between 
groups at 1 year in the rate of the first co-primary outcome 
of death, nonfatal stroke, nonfatal myocardial infarction, 
or nonfatal new renal failure requiring dialysis (HR =0.91; 
95% CI, 0.77–1.07; P=0.24). The rate of repeat coronary 
revascularization at 1 year was 1.4% in the OPCAB group 
and 0.8% in the ONCAB group (HR =1.66; 95% CI, 0.95–
2.89; P=0.07).
It is quite evident that there are notable differences 
between the two trials; CORONARY included more than 
twice as many participants than the ROOBY; furthermore, 
the participants in the CORONARY represented altogether 
a more heterogeneous group, whereas the ROOBY trial 
recruited patients exclusively from the VA system. The 
CORONARY specified a higher level of surgical ability at 
the beginning of the trial than was required in the ROOBY; 
each operation was performed by a surgeon who had more 
than 2 years of experience and had completed more than 
100 cases of the specific technique (either OPCAB or 
ONCAB). In CORONARY, trainees were not allowed to be 
the primary surgeon. The rate of conversion from OPCAB 
to ONCAB was lower in CORONARY than in the ROOBY 
(7.9% vs. 12.4%), and the rate of repeat revascularization 
between 31 days and 1 year was also lower in CORONARY 
(0.7% in the OPCAB and 0.6% in the ONCAB vs. 4.6% 
and 3.4%, respectively). Interestingly, in CORONARY, 
the rate of the primary end point was lower in the OPCAB 
group than in the ONCAB group (11.5% and 13.2%, 
respectively; P=0.08), whereas in the ROOBY, the rate was 
lower in the ONCAB group (9.4% in the OPCAB group vs. 
7.1% in the ONCAB group; P=0.08). 
The most recent Cochrane Review on OPCAB versus 
ONCAB (30), which did not include the CORONARY 
trial, was strongly influenced by the results from the 
ROOBY trial and concluded that OPCAB did not confer 
any significant benefit compared with ONCAB in relation 
to mortality, stroke or myocardial infarction. The authors 
observed better long-term survival in the group of patients 
undergoing ONCAB. Based on the current evidence, they 
suggested ONCAB to continue to be the standard surgical 
treatment, and OPCAB to be acceptable when there are 
contraindications for cannulation of the aorta and CPB.
A previous meta-analysis of propensity score analyses 
published by Kuss et al. (12) showed results contrasting 
the Cochrane Review conclusions: a total of 35 out of 58 
initially retrieved propensity score analyses were included, 
accounting for a total of 123,137 patients. The ROOBY trial 
was not enrolled in this meta-analysis. The estimated overall 
OR was less than 1 for all outcomes, favouring OPCAB. 
This benefit was statistically significant for mortality (OR 
=0.69; 95% CI, 0.60–0.75), stroke, renal failure, red blood 
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cell transfusion (P<0.0001), wound infection (P<0.001), 
prolonged ventilation (P<0.01), inotropic support (P=0.02), 
and intra-aortic balloon pump support (P=0.05). The odds 
ratios for myocardial infarction, atrial fibrillation, and 
reoperation for bleeding were not significant. These results 
agree with previous systematic reviews of randomized and 
nonrandomized trials (4).
Best available evidence for long-term survival
The increasing availability of longer-term data now 
requires follow up analysis; recent studies and meta-analysis 
have focused on long-term survival and major secondary 
outcomes in OPCAB vs. ONCAB within the general 
population (31).
Our group has previously reported the results from 
two prospective, randomized, controlled trials the Beating 
Heart Against Cardioplegic Arrest Study (BHACAS) 1 and 
2 trials (23): 401 participants were recruited overall, of whom 
200 patients had OPCAB and 201 patients underwent 
ONCAB surgery. The patients were followed up for 6 to 
8 years after surgical intervention to assess graft patency, 
major adverse cardiac-related events (MACEs), and health-
related quality of life (HRQoL). Patency was assessed 
using multidetector computed tomographic coronary 
angiographic analysis with a 16-slice scanner. Two blinded 
observers classified the proximal, the body and the distal 
segments of each graft as occluded or patent. MACEs 
and HRQoL were obtained from questionnaires given to 
participants and family practitioners. The mean follow-up 
period for OPCAB and ONCAB survival was 6.3 and 
6.4 years, respectively, and survival-free from MACEs or 
death was 5.4 and 5.2 years, respectively. The key findings 
(6 to 8 years after surgical intervention) are that there were 
no differences between the OPCAB and ONCAB groups in 
the hazard of death (HR =1.24; 95% CI, 0.72–2.15; P=0.44) 
or survival free from MACEs or death (HR =0.77; 95% CI, 
0.58–1.24; P=0.39). Patency was studied in 199 out of 349 
and HRQoL was studied in 299 out of 349 survivors. There 
was no evidence of attrition bias. The likelihood of graft 
occlusion was no different between OPCAB (10.6%) and 
ONCAB (11.0%) groups (OR =1.00; 95% CI, 0.55–1.81; 
P>0.99). Graft occlusion was more likely at the distal than 
the proximal anastomosis (OR =1.11; 95% CI, 1.02–1.20). 
More recently, our group reported a retrospective 
analysis of long term survival in actively treated diabetic 
patients undergoing OPCAB versus ONCAB (24). The 
final population consisted of 2,450 patients; of those, 1,493 
subjects were orally treated and 1,011 were on insulin. 
OPCAB and ONCAB were performed in 1,253 and 
1,197 patients respectively. Propensity score matching was 
used to compare the two groups. The results showed that 
OPACB did not significantly affect late mortality (HR 
=1.08; 95% CI, 0.92–1.28; P=0.32). However, OPCAB with 
incomplete revascularization was associated with a reduced 
survival rate when compared to OPCAB with complete 
revascularization (HR =1.82; 95% CI, 1.34–2.46; P=0.0002) 
and ONCAB with complete revascularization (HR =1.83; 
95% CI, 1.36–2.47; P<0.0001). Di Mauro et al. (11) 
conducted a retrospective cohort study of 2,833 patients 
with multivessel coronary disease. Two analyses comparing 
OPCAB and ONCAB were created with respect to 
preoperative normal and abnormal renal function: 
one analysis included 1,724 (862 each group) out of 
2,618 patients with normal preoperative creatinine 
(<1.5 mg/dL), and the second analysis included 160 (80 each 
group) out of 215 patients with preoperative abnormal renal 
function; in both analyses matched groups were selected 
applying propensity score. Mean follow up was 7.5 years. 
Ten-year mortality did not show any significant difference 
between ONCAB (7.0%) vs. OPCAB (5.3%) (HR =1.3; 
95% CI, 0.91–1.9; P=0.141). The authors concluded that 
OPCAB provides better late outcomes in patients with 
normal creatinine preoperatively, but similar outcomes for 
those with abnormal creatinine levels. The occurrence of 
acute renal failure significantly impairs early and long-term 
mortality and the surgical strategy does not influence late 
mortality in the overall population.
Raja et al. (25) reported the results of a retrospective 
cohort study of 704 consecutive patients with multivessel 
disease; 307 patients had OPCAB and 397 underwent 
ONCAB. The 307 OPCAB patients were propensity score 
matched to 307 ONCAB patients. The follow-up at 10 years 
was 100%. Survival was similar for the two cohorts. After 
adjusting for clinical covariates, OPCAB did not emerge as 
a significant independent predictor of long-term mortality 
(HR =0.91; 95% CI, 0.70–1.12), readmission to hospital 
for cardiac cause (HR =0.96; 95% CI, 0.78–1.10), or the 
need for re-intervention (HR =0.93; 95% CI, 0.87–1.05). 
OPCAB compared with ONCAB did not adversely impact 
on survival or freedom from re-intervention at 10-year 
follow-up.
Puskas et al. (3) reported the results of their prospective, 
randomized controlled trial [The Surgical Management 
of Arterial Revascularization Therapies (SMART) trial], 
enrolling 297 unselected patients with multivessel CAD. Of 
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140 survivors, 87 volunteered to return after a minimum 
of 6.8 years (maximum, 8.4 years; mean, 7.5 years) for 
assessment of graft patency and myocardial ischemia. Age 
at follow-up ranged from 38 to 90 years (mean, 68 years). 
There were 26 deaths from all causes among OPCAB 
patients and 31 among ONCAB patients. Graft patency 
was similar between groups among 622 grafts assessed by 
angiography before hospital discharge (99% OPCAB vs. 
97.7% ONCAB; P=0.22), among 511 grafts assessed by 
angiography at 1 year (93.6% OPCAB vs. 95.8% ONCAB; 
P=0.33), and among 190 grafts assessed by computed 
tomographic angiography at late follow-up (76% OPCAB 
versus 83.5% ONCAB; P=0.44). Twelve out of 34 OPCAB 
(35.3%) and 16 out of 39 ONCAB patients (41.0%) had 
any ischemia on positron emission tomography scanning 
(P=0.62). Four OPCAB patients (11.8%) and 9 ONCAB 
patients (23.1%) had an ischemic region in excess of 10% of 
myocardium (P=0.21). At late follow-up, recurrent angina 
had occurred in 11 of 43 (25.6%) OPCAB patients and 
5 of 44 (11.4%) ONCAB patients (P=0.09). Percutaneous 
re-intervention had been performed at the discretion 
of blinded local cardiologists in 1 of 43 (2.3%) OPCAB 
patients and 1 of 44 (2.3%) ONCAB patients (P=1.0). 
No patient in either group has undergone repeat CABG. 
The authors concluded that OPCAB and ONCAB 
were associated with similar early and late graft patency, 
incidence of recurrent or residual myocardial ischemia, 
need for re-intervention, and long-term survival.
Kirmani et al. (26) recently presented the results of 
a retrospective cohort study of patients undergoing 
isolated CABG at a single centre. A total of 8,055 patients 
were identified, with a median follow-up of 7.0 years. 
Propensity score matching was performed on the basis of 
on demographic variables and two groups of 2,082 patients 
for both OPCAB and ONCAB were obtained. The results 
showed that in the OPCAB group, there were significantly 
fewer in hospital cerebrovascular complications (0.5% vs. 
1.1%; P=0.017), and mean length of stay was shorter (7.6 vs. 
8.1 days; P<0.0001). The mean number of grafts was higher 
in the ONCAB group (3.28±0.94 vs. 3.10±1.10; P<0.0001). 
The authors concluded that despite a lower mean number 
of grafts, long-term survival after OPCAB was not inferior 
to long-term survival after ONCAB (P=0.167).
Hueb et al. (27) reported the results of a prospective, 
randomized controlled trial (MASS III) of 308 patients 
undergoing CABG. Of those patients, 155 underwent 
OPCAB and 153 had ONCAB. The follow-up was 
at 5 years. Primary composite end points were death, 
myocardial infarction, further revascularization (surgery or 
angioplasty), or stroke. After 5-year follow-up, the primary 
composite end point was not different between groups (HR 
=0.71; 95% CI, 0.41–1.22; P=0.21). The number of grafts 
per patient was higher in the ONCAB than the OPCAB 
group (2.97 vs. 2.49 grafts/patient; P=0.001). The authors 
concluded that no difference was found between groups 
in the primary composite end point at 5-year follow-up. 
Although OPCAB surgery was related to a lower number 
of grafts and higher episodes of atrial fibrillation, it had no 
significant implications related to long-term outcomes.
Similar results were demonstrated by Robertson et al. (19) 
in a retrospective cohort study of 1,285 patients. Following 
propensity-score matching for baseline characteristics, they 
reviewed the results of 308 patients undergoing OPCAB 
compared with 308 patients who had ONCAB. Survival 
and readmission for cardiac causes were monitored for up 
to 10 years postoperatively, with a median follow-up period 
of 5.9 years. The frequency of complete revascularization 
was significantly different between the 2 groups (OPCAB, 
79.2% vs.  ONCAB 88.3%; P=0.002). The OPCAB 
group had a significantly higher rate of total arterial 
grafting (OPCAB, 66.6% vs. ONCAB, 49.7%; P=0001). 
No difference was seen in 8-year survival or freedom 
from cardiac cause and hospital readmission between the 
2 groups.
Bakaeen et al. (16) recently published the results of their 
large multicentre retrospective review of all primary isolated 
CABG procedures performed at VA hospitals during a 
13.5-year period. Their objective was to compare risk-
adjusted long-term survival between patients who 
underwent ONCAB vs. OPCAB. Using VA Continuous 
Improvement in Cardiac Surgery Program, they identified 
all VA patients (n=65,097) who underwent primary isolated 
CABG from October 1997 to April 2011. The primary 
outcome measure was all-cause mortality. A greedy-match 
algorithm using the propensity scores matched 8,911 
OPCAB with 26,733 ONCAB patients.
For the matched cohort, the median follow-up was 
6.7 years (interquartile range, 3.72–9.35 years). Risk-
adjusted mortality did not differ significantly between the 
OPCAB and ONCAB groups at 1 year (4.67% vs. 4.78%; RR 
=0.98; 95% CI, 0.88–1.09) or 3 years (9.21% vs. 8.89%; RR 
=1.04; 95% CI, 0.96–1.12). However, risk-adjusted mortality 
was higher in the OPCAB group at 5 years (14.47% vs. 
13.45%; RR =1.08; 95% CI, 1.02–1.15) and 10 years 
(25.18% vs. 23.57%; RR =1.07; 95% CI, 1.03–1.12). 
Overall, the hazard ratio for OPCAB vs. ONCAB was 1.06 
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(95% CI, 1.00–1.13; P=0.04).
They concluded that OPCAB may be associated with 
decreased long-term survival.
Filardo et al. (17) published a retrospective cohort 
study of 8,081 consecutive patients; 732 patients had 
OPCAB, 7,349 underwent ONCAB. A propensity-adjusted 
model controlling for preoperative risk factors identified 
by the Society of Thoracic Surgeons (STS) and other 
preoperative clinical and nonclinical details was used to 
assess adjusted long-term mortality differences between 
OPCAB and ONCAB. Their results showed that ten-
year unadjusted survival was 54.7% (95% CI, 47.2–61.6%) 
in OPCAB patients and 62.3% (95% CI, 60.9–63.8%) in 
ONCAB patients. The log-rank test (P=0.012) indicated 
a significantly higher risk of death in OPCAB patients. 
After adjustment, the risk of death remained significantly 
higher in the OPCAB patients (HR =1.18; 95% CI, 
1.02–1.38). The authors concluded that for multivessel 
coronary disease, ONCAB might be preferable to OPCAB 
given that it may achieve a more complete and durable 
revascularization.
Takagi et al. (15) recently published the results of a meta-
analysis including 5 randomized controlled trials and 17 
observational studies, enrolling a total of 104,306 patients. 
A pooled analysis of all 22 studies demonstrated a 
statistically significant 7% increase in long-term all-cause 
mortality with OPCAB relative to ONCAB (HR =1.07; 
95% CI, 1.03–1.11; P=0.0003). Although a pooled analysis 
of 5 randomized trials (1,486 patients) demonstrated a 
statistically nonsignificant 14% increase in mortality with 
OPCAB relative to ONCAB (HR =1.14; 95% CI, 0.84–1.56; 
P=0.39), another pooled analysis of 17 observational studies 
(102,820 patients) demonstrated a statistically significant 
7% increase in mortality with OPCAB relative to ONCAB 
(HR =1.07; 95% CI, 1.03–1.11; P=0.0004). The authors 
concluded that OPCAB is likely associated with worse long-
term (>5-year) survival compared with ONCAB. 
The findings of this meta-analysis must be interpreted 
with caution as the results are strongly influenced by the 
ROOBY trial (28) which, as already mentioned, has received 
a lot of criticism and has several important limitations. 
Discussion
There has been increasing interest in OPCAB over the 
last two decades on the basis of the clinical advantages 
attributed to avoiding CPB during CABG. The most 
notable merits, as suggested by several observational 
studies, included avoiding embolic stroke caused by invasive 
aortic manipulation and reducing coagulopathy and renal 
dysfunction (2-14). However, the expected benefit on long 
term survival is still debated. To date, results of the largest 
randomized trials are limited to within 1 year of surgery and 
the long term comparative data regarding clinical outcomes 
between the 2 strategies are currently unavailable (28,29). 
Despite initial enthusiasm, concerns have been raised 
regarding the risk of incomplete revascularization and 
higher rate of graft failure with OPCAB. These potential 
drawbacks have been related to poorer long term survival 
after OPCAB reported in sporadic studies (16,17). 
Incomplete revascularization of patients with multivessel 
coronary artery disease is an independent risk factor for 
increased long-term mortality after CABG (32) and has 
been related to inferior cardiac survival after 5 years of 
follow-up compared with complete revascularization (33). 
The criticism regarding completeness of revascularization 
with OPCAB seems no longer valid in the current era as 
technology to securely perform multivessel OPCAB has 
improved significantly; in fact, the majority of evidence from 
randomized trials suggests at least equivalent completeness 
of revascularization with OPCAB and ONCAB (3,8,29,30). 
It is interesting to note that in those trials where OPCAB 
was associated with incomplete revascularization it is 
impossible to determine myocardial viability in the territory 
left ungrafted, because myocardial viability studies were not 
used, so the significance of a reduced number of grafts in the 
OPCAB cohort is uncertain. Moreover, none of the trials 
or studies reporting incomplete revascularization provides 
an explanation for failure to completely revascularize the 
OPCAB group.
In our review, most of the available comparisons found 
similar survival rates after OPCAB vs. ONCAB, especially 
when OPCAB is performed in high volume centres, thus 
supporting the view that OPCAB is as effective as ONCAB 
in terms of late survival. It should be underlined that 
substantial variability between the studies in terms of risk 
profile, selection criteria and expertise of surgeons limits 
the generalizability of any conclusions. The frequency of 
complete revascularization reported by different studies 
comparing OPCAB and ONCAB is strongly influenced by 
relative experience with each technique of the reporting 
centre and surgeon, highlighting once more the importance 
of a learning curve as well as case load. These differences 
can also have an impact on the final completeness of 
revascularization achieved by multicentre randomized trials.
Graft failure is one of the major determinants of clinical 
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prognosis after CABG. There has been considerable concern 
among surgeons and cardiologists that the higher technical 
difficulty of OPCAB might translate into less precise 
anastomoses and subsequently reduced graft patency (34). 
A precipitous learning curve, distractions caused by cardiac 
motion or pulmonary insufflations, and performing the 
anastomoses on a moving target have been considered 
as factors accountable for poorer graft patency after 
OPCAB (35). Interestingly, the concerns about suboptimal 
graft patency over the last years have been largely influenced 
by the results of the ROOBY trial (28), whose findings have 
been strongly criticised since the 53 participating surgeons 
enrolled on average only eight patients per year during the 
study period and had unacceptably high conversion rates to 
on-pump surgery (12%) and incomplete revascularization 
(18%). Moreover, in 60% of the cases a junior resident was 
the primary surgeon. Another unrecognized confounder 
that contributed to poor graft patency in the ROOBY trial 
was the concomitant use of endoscopic vein harvesting 
(EVH) in 1,471 patients (ONCAB =907 and OPCAB =564). 
The incidence of a patient having 1 or more occluded 
saphenous vein grafts on follow-up angiography was 41.3% 
in the EVH group, compared with 28.0% in the open 
vein harvesting (OVH) group (P<0.0001). Since ROOBY 
trial was recruiting at a time when EVH was not being 
widely practiced, the poor vein graft patency secondary to 
EVH can be attributed to the learning curve and relative 
inexperience of the vein harvesters. Poor conduit quality, an 
unavoidable consequence of the learning curve for EVH, 
has been found to be a significant predictor of early graft 
failure (36).
Conclusions
In view of the increasing risk profile of patients currently 
referred to coronary artery bypass surgery and potential 
benefit from OPCAB in reducing operative morbidity, 
current evidence suggest that OPCAB should still be 
considered a valuable strategy. Undoubtedly, better results 
using the OPCAB technique are achieved by specialised 
groups completely committed to this surgical technique. 
OPCAB is more technically complex and completeness 
of revascularization is strongly influenced by surgeon and 
centre volume and expertise.
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